These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 2433021)
21. Inhibition of pre-mRNA splicing by cisplatin and platinum analogs. Schmittgen TD; Ju JF; Danenberg KD; Danenberg PV Int J Oncol; 2003 Sep; 23(3):785-9. PubMed ID: 12888918 [TBL] [Abstract][Full Text] [Related]
22. Preparation, characterization, and anticancer activity of a series of cis-PtCl2 complexes linked to anthraquinone intercalators. Gibson D; Gean KF; Ben-Shoshan R; Ramu A; Ringel I; Katzhendler J J Med Chem; 1991 Jan; 34(1):414-20. PubMed ID: 1992142 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and antitumor activity of a new cis-diammineplatinum (II) complex containing procaine hydrochloride. Cafaggi S; Esposito M; Parodi B; Vannozzi MO; Viale M; Pellecchia C; Fulco RA; Merlo F; Zicca A; Cadoni A Anticancer Res; 1992; 12(6B):2285-92. PubMed ID: 1295476 [TBL] [Abstract][Full Text] [Related]
24. Increased therapeutic efficacy of cis-platinum complexes of poly-L-glutamic acid against a murine carcinoma. Schechter B; Wilchek M; Arnon R Int J Cancer; 1987 Mar; 39(3):409-13. PubMed ID: 2434442 [TBL] [Abstract][Full Text] [Related]
25. A comparative study of the cytotoxicity and DNA-damaging effects of cis-(diammino)(1,1-cyclobutanedicarboxylato)-platinum(II) and cis-diamminedichloroplatinum(II) on L1210 cells. Micetich KC; Barnes D; Erickson LC Cancer Res; 1985 Sep; 45(9):4043-7. PubMed ID: 3896476 [TBL] [Abstract][Full Text] [Related]
26. Cytotoxic activity and chemical reactivity of cis-platinum(II) and trans-palladium(II) complexes with diethyl (pyridinylmethyl)phosphates. Kalinowska-Lis U; Szmigiero L; Studzian K; Ochocki J Eur J Med Chem; 2009 Feb; 44(2):660-4. PubMed ID: 18586354 [TBL] [Abstract][Full Text] [Related]
27. In vitro characteristics and in vivo plasma disposition of cisplatin conjugated with oxidized and dicarboxymethylated dextrans. Nakashima M; Ichinose K; Kanematsu T; Masunaga T; Ohya Y; Ouchi T; Tomiyama N; Sasaki H; Ichikawa M Biol Pharm Bull; 1999 Jul; 22(7):756-61. PubMed ID: 10443480 [TBL] [Abstract][Full Text] [Related]
28. Toxicity, mutagenicity, intracellular drug concentration and DNA binding in Escherichia coli treated with cis-platinum(II) complexes. Razaka H; Wimmer F; Wimmer S; Villani G; Johnson NP Chem Biol Interact; 1987 Mar; 61(3):265-75. PubMed ID: 3552271 [TBL] [Abstract][Full Text] [Related]
29. [Transient electrical birefringence study of the interaction between DNA and platinum compounds: cis-DDP, trans-DDP and TDP]. Mallet G; Vasilescu D Pathol Biol (Paris); 2001 Feb; 49(1):41-6. PubMed ID: 11265222 [TBL] [Abstract][Full Text] [Related]
30. [Acute and subacute toxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in laboratory rodents]. Härtl A; Güttner J; Horn U; Jelinek F; Stöckel U; Schröer HP; Hoffmann H Arch Geschwulstforsch; 1989; 59(4):239-44. PubMed ID: 2640563 [TBL] [Abstract][Full Text] [Related]
31. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts. Kasparkova J; Novakova O; Farrell N; Brabec V Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292 [TBL] [Abstract][Full Text] [Related]
32. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes. Siddik ZH; al-Baker S; Thai G; Khokhar AR Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929 [TBL] [Abstract][Full Text] [Related]
33. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines. Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637 [TBL] [Abstract][Full Text] [Related]
34. Synthesis and antitumor activity of seleno- and thio-purines complexed with cis-diamminoplatinum (II). Maeda M; Abiko N; Sasaki T J Pharmacobiodyn; 1982 Feb; 5(2):81-7. PubMed ID: 7201515 [TBL] [Abstract][Full Text] [Related]
35. Atopic hypersensitivity to cis-dichlorodiammineplatinum(II) and other platinum complexes. Khan A; Hill JM; Grater W; Loeb E; MacLellan A; Hill N Cancer Res; 1975 Oct; 35(10):2766-70. PubMed ID: 50881 [TBL] [Abstract][Full Text] [Related]
36. Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients. Terheggen PM; Dijkman R; Begg AC; Dubbelman R; Floot BG; Hart AA; den Engelse L Cancer Res; 1988 Oct; 48(19):5597-603. PubMed ID: 3046743 [TBL] [Abstract][Full Text] [Related]
37. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Knox RJ; Friedlos F; Lydall DA; Roberts JJ Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077 [TBL] [Abstract][Full Text] [Related]
38. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines. Yoshida M; Khokhar AR; Siddik ZH Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968 [TBL] [Abstract][Full Text] [Related]
39. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands. Kido Y; Khokhar AR; al-Baker S; Siddik ZH Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629 [TBL] [Abstract][Full Text] [Related]
40. Synthesis and in vitro antitumor activity of platinum acetonimine complexes. Boccarelli A; Intini FP; Sasanelli R; Sivo MF; Coluccia M; Natile G J Med Chem; 2006 Jan; 49(2):829-37. PubMed ID: 16420068 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]